What is Quanta Dialysis Technologies?
Quanta Dialysis Technologies is a pioneering force in the medtech industry, dedicated to redefining the standard of care for patients requiring dialysis. By developing the Quanta Dialysis System, the company addresses the persistent challenges of accessibility and cost, enabling high-quality treatment in a variety of settings beyond traditional clinical facilities. Its market position is defined by a commitment to engineering excellence and a patient-centric approach that seeks to improve outcomes through technological innovation.
The company operates at the intersection of healthcare and advanced engineering, leveraging its proprietary systems to provide flexible, efficient, and reliable dialysis solutions. As the demand for decentralized care models grows, Quanta Dialysis Technologies remains at the forefront, providing the infrastructure necessary to support patients and healthcare providers in managing chronic kidney disease with greater autonomy and precision.
How much funding has Quanta Dialysis Technologies raised?
Quanta Dialysis Technologies has raised a total of $405.6M across 5 funding rounds:
Series A
$14.3M
Series B
$38.3M
Series C
$48M
Series D
$245M
Series E
$60M
Series A (2009): $14.3M with participation from Seroba Life Sciences, Wellington Partners, btov Partners, and NBGI Ventures
Series B (2014): $38.3M led by Air Liquide
Series C (2019): $48M supported by Wellington Partners, btov Partners, and Seroba Life Sciences
Series D (2021): $245M featuring Sands Capital, BlackRock, Eldridge Capital, Novo Holdings, and Glenview Capital Management
Series E (2024): $60M backed by Glenview Capital Management, B2venture, and Novo Holdings
Key Investors in Quanta Dialysis Technologies
Glenview Capital Management
Glenview Capital Management is a leading hedge fund and investment management firm based in New York, known for its fundamental, research-driven investment strategies and deep sector expertise in healthcare.
Novo Holdings
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focusing on long-term investments in life sciences.
B2venture
b2venture is a European venture capital firm that invests in early-stage startups, focusing on innovative ideas and ambitious entrepreneurs within the healthcare and digital technology sectors.
What's next for Quanta Dialysis Technologies?
Looking ahead, the strategic deployment of the $60M will likely focus on scaling manufacturing capabilities and expanding the footprint of the Quanta Dialysis System in key global markets. The company is expected to leverage its strong balance sheet to drive further clinical adoption and potentially explore new therapeutic applications for its core technology. By maintaining its focus on operational efficiency and technological advancement, Quanta Dialysis Technologies is poised to solidify its leadership in the renal care space, ensuring that its innovative solutions reach a broader patient population while delivering sustainable value to its stakeholders.
See full Quanta Dialysis Technologies company page
